Cardiomedex’s Partners

Cardiomedex works with highly specialized partners to extend its range of services and provide a global overview of drug development programs.

PHYSIOGENEX

Physiogenex is a preclinical CRO specialized in metabolic disorders, based in Toulouse, France. They have been developing and applying their expertise in metabolic diseases for more than 15 years in order to provide reliable preclinical studies for the treatment of these pathologies. They develop innovative models for all metabolic diseases and their complications as well as a wide range of tests to demonstrate the effectiveness of drug candidates.

Physiogenex and Cardiomedex work in close collaboration with each other as they share the same CEO and facilities. Together, our two companies can provide a fully integrated approach to cardiometabolic diseases, enabling us to design large-scale studies to evaluate the effect of drug candidates on both cardiac and metabolic functions in predictive and integrative models.

Visit the Physiogenex website for more information.